South Korea · Delayed Price · Currency is KRW Hanmi Pharm. Statistics
Total Valuation
Hanmi Pharm. has a market cap or net worth of KRW 5.83 trillion. The enterprise value is 6.24 trillion.
| Market Cap | 5.83T |
| Enterprise Value | 6.24T |
Important Dates
The next confirmed earnings date is Thursday, April 30, 2026.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
Hanmi Pharm. has 12.68 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 12.68M |
| Shares Outstanding | 12.68M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 7.81% |
| Owned by Institutions (%) | 19.22% |
| Float | 6.26M |
Valuation Ratios
The trailing PE ratio is 34.43 and the forward PE ratio is 33.10. Hanmi Pharm.'s PEG ratio is 1.50.
| PE Ratio | 34.43 |
| Forward PE | 33.10 |
| PS Ratio | 3.77 |
| PB Ratio | 4.10 |
| P/TBV Ratio | 4.87 |
| P/FCF Ratio | 44.85 |
| P/OCF Ratio | 33.70 |
| PEG Ratio | 1.50 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.34, with an EV/FCF ratio of 47.97.
| EV / Earnings | 36.80 |
| EV / Sales | 4.03 |
| EV / EBITDA | 19.34 |
| EV / EBIT | 27.87 |
| EV / FCF | 47.97 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.31.
| Current Ratio | 1.48 |
| Quick Ratio | 0.90 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 1.35 |
| Debt / FCF | 3.34 |
| Interest Coverage | 13.18 |
Financial Efficiency
Return on equity (ROE) is 14.05% and return on invested capital (ROIC) is 12.22%.
| Return on Equity (ROE) | 14.05% |
| Return on Assets (ROA) | 6.73% |
| Return on Invested Capital (ROIC) | 12.22% |
| Return on Capital Employed (ROCE) | 14.61% |
| Weighted Average Cost of Capital (WACC) | 7.36% |
| Revenue Per Employee | 644.80M |
| Profits Per Employee | 70.65M |
| Employee Count | 2,400 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 2.07 |
Taxes
In the past 12 months, Hanmi Pharm. has paid 26.34 billion in taxes.
| Income Tax | 26.34B |
| Effective Tax Rate | 12.34% |
Stock Price Statistics
The stock price has increased by +85.22% in the last 52 weeks. The beta is 0.45, so Hanmi Pharm.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +85.22% |
| 50-Day Moving Average | 523,840.00 |
| 200-Day Moving Average | 422,030.00 |
| Relative Strength Index (RSI) | 35.92 |
| Average Volume (20 Days) | 84,606 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hanmi Pharm. had revenue of KRW 1.55 trillion and earned 169.55 billion in profits. Earnings per share was 13,362.00.
| Revenue | 1.55T |
| Gross Profit | 884.41B |
| Operating Income | 223.87B |
| Pretax Income | 213.48B |
| Net Income | 169.55B |
| EBITDA | 322.68B |
| EBIT | 223.87B |
| Earnings Per Share (EPS) | 13,362.00 |
Balance Sheet
The company has 201.32 billion in cash and 434.21 billion in debt, with a net cash position of -232.89 billion or -18,366.35 per share.
| Cash & Cash Equivalents | 201.32B |
| Total Debt | 434.21B |
| Net Cash | -232.89B |
| Net Cash Per Share | -18,366.35 |
| Equity (Book Value) | 1.42T |
| Book Value Per Share | 98,559.56 |
| Working Capital | 288.75B |
Cash Flow
In the last 12 months, operating cash flow was 173.07 billion and capital expenditures -43.02 billion, giving a free cash flow of 130.05 billion.
| Operating Cash Flow | 173.07B |
| Capital Expenditures | -43.02B |
| Depreciation & Amortization | 98.81B |
| Net Borrowing | -66.33B |
| Free Cash Flow | 130.05B |
| FCF Per Share | 10,255.96 |
Margins
Gross margin is 57.15%, with operating and profit margins of 14.47% and 10.96%.
| Gross Margin | 57.15% |
| Operating Margin | 14.47% |
| Pretax Margin | 13.79% |
| Profit Margin | 10.96% |
| EBITDA Margin | 20.85% |
| EBIT Margin | 14.47% |
| FCF Margin | 8.40% |
Dividends & Yields
This stock pays an annual dividend of 1,250.00, which amounts to a dividend yield of 0.26%.
| Dividend Per Share | 1,250.00 |
| Dividend Yield | 0.26% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 7 |
| Payout Ratio | 18.20% |
| Buyback Yield | -0.07% |
| Shareholder Yield | 0.19% |
| Earnings Yield | 2.91% |
| FCF Yield | 2.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.02.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
Hanmi Pharm. has an Altman Z-Score of 5.1 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.1 |
| Piotroski F-Score | 6 |